Thus, targeting of S6K1/S6K2 requires AXL inhibition in a kinase-directed therapeutic approach that exploits the vulnerability of PTEN-deficient GBM by disruption of pyrimidine biosynthesis. This evidence concerns the gene PTEN and glioblastoma.